

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2013

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	30-0520478
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4520 East-West Highway, 3 rd Floor Bethesda, Maryland		20814
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On June 26, 2013, the Sucampo Pharmaceuticals, Inc. ("Company") will make corporate update presentations at one-on-one meetings with investors in Boston, Massachusetts. All meetings will include modifications to 13 slides from those slides filed on Form 8K dated June 6, 2013. The additional slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The modifications of the 13 slides to the corporate update presentation slides dated June 26, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: June 26, 2013

By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp
Title: EVP, Chief Legal Officer and
Corporate Secretary

Sucampo: Leader in Gastroenterology with Three Approved Indications for AMITIZA

- **CIC**

- Globally, CIC affects ~14%–16%^{2,3} and CIC accounts for 92,000 hospitalizations/yr in US⁴

- **IBS-C**

- IBS-C affects ~5% of adult population globally⁵
- Patients with IBS consume >50% more healthcare resources than those without IBS⁶ and the direct and indirect costs of IBS care in the US equal \$20 billion/yr⁵
- Severe constipation is associated with increased cardiovascular risk in women^{7,8}

- **OIC**

- More than 230M prescriptions for opioid use in the U.S. annually⁹; OIC affects around 4.5M of these patients (2.5M are moderate to severe)¹⁰
- Constipation is the most common reason for discontinuation of opioid therapy and longest lasting common side effect of chronic opioids⁹
- Currently no other approved oral prescription products on the market¹¹
- Increases cost of care and decreases HRQOL⁹

See References 2-11

- **OIC indication approved in April 2013**
 - Priority review for first and only medicine for the treatment of OIC in adults with chronic, non-cancer pain
 - \$10M milestone payment received
 - Partner Takeda's reps began selling week of May 13
 - Strategy to build awareness that AMITIZA is the first and only medicine for OIC among PCPs and pain specialists
- **Strong AMITIZA YOY Growth**
 - Q1 TRx growth: +4% YoY
 - Q1 net sales increase: +7% YoY to \$64.9M
 - Growth continuing: TRx +5% YoY through May
 - New competitor is creating more awareness and growing the market
- **Over 7M prescriptions over 7 years**
 - Expect to rise substantially




Near-Term Strategy to Grow AMITIZA

Target	Goal
PCPs who already write AMITIZA	+OIC
Pain Specialists	
GIs	

Target	Goal
PCP Non-Writers	+CIC +IBS-C +OIC

Competitive Landscape in OIC

EXPECT NO MARKET CHALLENGE FOR AMITIZA USE FOR OIC NON-CANCER PATIENTS FOR UP TO 2 YEARS



See Reference 11

Japan

- First-ever prescription medicine approved for chronic constipation
- All launch metrics have been surpassed: revenue and patient numbers tracking above expectation
- Sucampo recorded \$2.2M of product sales revenue in Q1, double our internal forecast

Europe

- Initiated NICE endorsement process in UK following CIC approval; expect Q2 2014
- Initiated MRP (CIC) in additional EU markets
- OIC indication filed in both Switzerland and UK
- Commenced active marketing (CIC) in Switzerland


We have also received expressions of interest from potential partners for AMITIZA for new indications and new territories, including Europe, Asia and emerging markets

- **Glaucoma is age-related and the second leading cause of bilateral blindness worldwide; will affect an estimated 79.6M people worldwide by 2020¹³**
 - Reduction in intra-ocular pressure (IOP) is currently the only modifiable risk factor for patients with glaucoma and ocular hypertension¹³
 - Direct cost (health care expenses) of eye disorders and vision loss in the US in 2013 is estimated to be \$66.8B¹⁴
 - Glaucoma accounts for \$5.8B¹⁴
- **Compliance and adherence are unmet needs**
 - 50% of new patients drop off therapy within one year of initiation¹⁵
 - Hyperemia is the #1 reason for discontinuation of prostaglandins, often chosen as first line therapy¹⁶



Unique Considerations for Glaucoma Treatment in Elderly Patients

- **More than 11M Americans are ≥ 80 years of age²²**
 - Age is an independent risk factor for glaucoma¹⁸
- **Elderly patients generally have greater susceptibility to the systemic adverse effects of glaucoma medications²³**



See References 18,22-23; for chart see Reference 24

RESCULA Launch Update

- **Positive feedback and significant progress**

- Efforts focused on ophthalmologists and optometrists
- More than 22,000 calls have already been made
- Over 78,000 samples have been shipped
- Expect sales to increase in 2H



- **Aggressively pursuing managed care coverage for RESCULA**

- Over 100 face to face meetings with plans and PBMs
- Strong reception from plans

- **Route to Savings™: Committed to Patient Access**

- 33% of RESCULA TRxs going through RTS Program
- Commercial co-pay reductions seen from \$55 - \$18

RESCULA
(Uroprostane isopropyl
ophthalmic solution) 0.15%

RESCULA ROUTE TO SAVINGS® CARD
Pay-No-More-Than \$20*
up to \$100.00 off per prescription.

Call 1-888-838-9914 to determine your eligibility and activate your card. Once activated, give this card to your pharmacist, along with a valid prescription from your physician.

RxBIN#	PCN#	GROUP#	IDENTIFICATION#
015251	PRX2000	RES01	RE011012018

www.RESCULA.com
EXP DATE: 06/30/2014

SUCAMPO

Key Facts

Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (06-24-13), 52-Week Range	\$6.55, \$10.48 to \$3.78
Shares Outstanding (06-24-13)	42.3M (1 class of common stock)
Daily Volume (90-day average)	242,322
Market Capitalization (06-24-13)	\$276.9M
Debt (03-31-13)	\$62.5M
Cash & Equivalents (03-31-13)	\$95.8M
Enterprise Value (06-24-13)	\$243.5M
Full-time Employees (06-24-13)	115
Fiscal Year Ends	December 31
Accounting Firm	PricewaterhouseCoopers LLP

Terms of Sucampo's AMITIZA Agreements

- **Takeda Agreement**

- Takeda shall promote, market, and sell AMITIZA in US and Canada
- Sucampo's tiered royalty rate: 18%–26% of annual net sales
- Sucampo earned \$20M in upfront and \$130M in development milestone payments as of 03/31/13
 - Sucampo received \$10M milestone payment following the first OIC sale
- Sucampo received \$109M in reimbursement for R&D expenses from Takeda as of 03/31/13

- **Abbott Japan Agreement**

- Abbott Japan shall promote, market, and sell AMITIZA for CIC in Japan
- Sucampo will sell product to Abbott Japan at discount to Abbott Japan's approved reimbursement price
- Sucampo earned \$10M in upfront and \$27.5M in development milestone payments as of 03/31/13

Issued Lubiprostone Patents (cont'd)

Japanese

<u>Patent No.</u>	<u>Expires</u>	<u>Type of Patent</u>
4,332,316	2023	Composition of matter (drug substance and drug product)
4,332,353	2022	Therapeutic use (treating OIC)
4,684,334	2023	Therapeutic use (treating constipation)
4,783,794	2028	Composition of matter (drug product)
4,786,866	2023	Therapeutic use (treating constipation)
4,852,229	2023	Therapeutic use (treating constipation)
4,889,219	2024	Therapeutic use (treating IBS)

European

<u>Patent No.</u>	<u>Expires</u>	<u>Type of Patent</u>
1,220,849	2020	Composition of matter (drug product)
1,315,485	2021	Therapeutic use (treating constipation)
1,392,318	2022	Therapeutic use (treating OIC)
1,426,361	2020	Composition of matter (drug substance)
1,443,938	2022	Therapeutic use (treating constipation)

References

1. Sucampo data on file.
2. Soares et al. *Am J Gastroenterol*. 2011
3. Kantar Health Epi database <http://epidb.khapps.jp>
4. Lembo et al. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*. 2010
5. Saito et al. *Am J Gastroenterol*. 2002
6. Hulisz D. *J Manag Care Pharm*. 2004
7. Salmoirago-Blotcher et al. *Am J Med*. 2011
8. Talley et al. *Am J Gastroenterol*. 2001
9. Manchikanti L, et al. Pain Physician. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. 2012 Jul;15(3 Suppl):S67-116.
10. Clearview Analysis 2008
11. Internal Research
12. AMITIZA Physician ATU W11 2013
13. Quigley et al. *Br J Ophthalmol* 2006 Mar;90(3):252-7
14. Private Blindness America. 2013. <http://costofvision.preventblindness.org/>
15. Fain JM et al. A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. *BMC Ophthalmol*. 2011 Jun 13;11(1):13. doi: 10.1186/1471-2415-11-13.
16. Zimmerman TJ et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. *J Ocul Pharmacol Ther*. 2009 Apr;25(2):145-52. doi: 10.1089/jop.2008.0072.
17. RESCULA Package Insert
18. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guideline: Primary open-angle glaucoma. 2010
19. Kass MA et al. *Arch Ophthalmol*. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. 2002 Jun;120(6):701-13; discussion 829-30.
20. Based on Dec 2009 - Nov 2012 IMS NSP data
21. Based on Dec 2009 – Nov 2012 MATTY IMS NPA data

References (cont'd)

22. American Academy of Ophthalmology Glaucoma Basic and Clinical Science Course 2012-2013
23. Kaiserman I et al. Topical beta blockers in asthmatic patients-is it safe? *Curr Eye Res.* 2009 Jul;34(7):517-22.
24. Based on US Census Bureau data from May 2010 and November 2011 *The Older Population: 2010 (November 2011) & US Census Bureau THE NEXT FOUR DECADES The Older Population in the United States: 2010 to 2050 (May 2010)*
25. Gottfredsdottir MS et al. Physicians' guide to interactions between glaucoma and systemic medications. *J Glaucoma.* 1997 Dec;6(6):377-83.
26. Based on Dec 2011- Nov 2012 MATTY IMS NPA data
27. RESCULA CVA
28. Joswick et al. *Digestive Disease Week, 2012*
29. AMITIZA Package Insert

AMITIZA and RESCULA are registered trademarks of Sucampo AG. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG.